NOVEL G-QUADRUPLEX BINDERS WITH POTENTIAL FOR A DUAL DNA CROSS-LINKING MECHANISM OF ACTION by Duncan, Nathan S
University of Montana 
ScholarWorks at University of Montana 
Graduate Student Theses, Dissertations, & 
Professional Papers Graduate School 
2013 
NOVEL G-QUADRUPLEX BINDERS WITH POTENTIAL FOR A DUAL 
DNA CROSS-LINKING MECHANISM OF ACTION 
Nathan S. Duncan 
The University of Montana 
Follow this and additional works at: https://scholarworks.umt.edu/etd 
Let us know how access to this document benefits you. 
Recommended Citation 
Duncan, Nathan S., "NOVEL G-QUADRUPLEX BINDERS WITH POTENTIAL FOR A DUAL DNA CROSS-
LINKING MECHANISM OF ACTION" (2013). Graduate Student Theses, Dissertations, & Professional 
Papers. 710. 
https://scholarworks.umt.edu/etd/710 
This Thesis is brought to you for free and open access by the Graduate School at ScholarWorks at University of 
Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an 
authorized administrator of ScholarWorks at University of Montana. For more information, please contact 
scholarworks@mso.umt.edu. 
NOVEL G-QUADRUPLEX BINDERS WITH 
POTENTIAL FOR A DUAL DNA CROSS-LINKING 
MECHANISM OF ACTION 
By 
NATHAN S. DUNCAN 
B.S. Biochemistry, Missouri Southern State University, Joplin, Missouri, 2010 
 
Thesis 
presented in partial fulfillment of the requirements 
for the degree of 
 
Master of Science 
in Medicinal Chemistry 
 
The University of Montana 
Missoula, Montana 
 
May 2013 
 
Approved by: 
 
Sandy Ross, Dean of The Graduate School 
Graduate School 
 
Nicholas R. Natale, Director, Medicinal Chemistry Program 
Department of Biomedical and Pharmaceutical Sciences 
 
Howard D. Beall 
Department of Biomedical and Pharmaceutical Sciences 
 
Michael R. Braden 
Department of Biomedical and Pharmaceutical Sciences 
 
Orion B. Berryman 
Department of Chemistry & Biochemistry 
 
 
 
 
ii 
 
Duncan, Nathan, M.S., Spring 2013        Medicinal Chemistry 
    
 
―Novel G-quadruplex Binders with Potential for a Dual DNA  
Cross-Linking Mechanism of Action‖ 
Chairperson:  Nicholas R. Natale 
 
Co-Chairperson:  Howard D. Beall, Michael R. Braden, Orion B. Berryman 
 
Genomic DNA is organized around the double-stranded of B-form DNA, which is 
both durable and flexible enough to store and pass on genetic information. Once freed 
from the associations of an extended complimentary sequence, single stranded DNA and 
RNA can adopt a vast array of stable secondary structure motifs, such as stem-loop, 
pseudo-knots, and tetra-loops, ideal for its involvement in biological settings other than 
as a store of genetic information. Originally, alkylating agents were used as "mustard 
gas" and related chemical weapons in World War I. Alkylating agents, in general, can 
react with one or two different 7-N-guanine residues and could potentially result in the 
cross-linkage of DNA strands, preventing uncoiling of the DNA double helix leading to 
cell death. More recent evidence show that guanine-rich nucleic acids can fold into 
distinctive four-stranded conformers found in telomeric DNA repeats (i.e. TTAGGG), 
also known as G-quadruplexes (G4), as well as in sequences in the promoter and other 
regulatory regions of genes, especially those involved in cellular proliferation. Small 
molecules that induce the formation of, and selectively bind to, G4 structures are of 
interest for development as potential anticancer therapeutics. Novel 10-oxoanthracene 
and substituted anthracenyl isoxazole esters (AIEs) were synthesized and characterized 
based on NMR studies. To date, quarfloxin is the only G-quadruplex ligand from the 
large number developed to progress to clinical evaluation. The synthesis, structural 
characterization, and biological studies will be presented. 
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1.1 Introduction 
 
 Gellert, Lipsett and Davies were the first to initially identify four-stranded helical 
arrangements in fibers of guanosine monophosphate in 1962, which would have made 
last year, 2012, the 50th anniversary of the birth of the quadruplex field.
1
 Genomic DNA, 
which is organized around double-stranded B-form DNA, is both durable and flexible 
enough to store and pass on genetic information. The standard of several secondary 
structural motifs, helical B-form DNA, utilizes an anti-parallel arrangement of two 
complimentary strands, stabilized by Watson-Crick base pairing (Figure 1). Once  
 
Figure 1. The dimensions of duplex DNA and its base pair surface. Reprinted from 
reference [6] with permission from the publisher. 
 
freed from the associations of an extended complimentary sequence, single stranded 
DNA and RNA can adopt a vast array of other stable secondary structure motifs, such as 
stem-loop, pseudo-knots, and tetra-loops, ideal for its involvement in other biological 
settings other than as a store of genetic information.
2
 Guanine-rich nucleic acids can fold 
 
 
2 
 
into distinctive four-stranded conformers found in telomeric DNA repeats (i.e. 
TTAGGG) as well as in sequences in the promoter and other regulatory regions of genes, 
especially those involved in cellular proliferation. 
3, 4 
The terminal 3’-telomeric 150–250 
nucleotides single-stranded DNA can be induced and stabilized by certain small 
molecules to form higher order G-quadruplex structures (Figure 2) that prevent the 
interaction and regulation of the telomerase enzyme complex (Figure 3) in cancer cells 
 
Figure 2. G-Quadruplex structure and G-quartet surface.  Reprinted from reference 
[6] with permission from the publisher. 
 
(which is over-expressed in ~80–90% 
4-6
), and thereby maintain telomere length 
homeostatis (acting as a tumor promoter). Loss of the telomerase enzyme deprotects the 
telomeres and initiates DNA damage-response mediated cell death since the enzyme can 
no longer synthesize any further telomeric DNA repeats (Figure 3).
3, 4, 7, 8 
G-rich 
sequences can utilize both the Watson-Crick and Hoogsteen faces of a guanine base to 
self-associate in a hydrated environment containing cations to form extended four 
 
 
3 
 
stranded stacked structures termed G-quadruplex or G-quartet (Figure 2). The stability of 
extended quadruplexes has fuelled research beyond biology into the development of nano 
wires and sensors.
2, 9, 10 
 
Quadruplex formation at the telomeric single-strand overhang (Figure 3) may 
itself be a DNA damage signal, producing responses analogous to those of other 
mediators of telomere damage. The biological function of induced telomeric 
quadruplexes remains to be fully clarified; an end-protective role has been suggested.
11-13
 
However, to date, there is no direct evidence of a role for telomeric G-quadruplexes in 
the functioning of telomeres in normal human cells.
4
 The working hypothesis is that the 
ligand stabilizes telomeric DNA into quadruplex structures that inhibit the primer from 
interacting as a single stranded species with the RNA template of telomerase. The 
approach to target quadruplexes overrides the problem of telomerase resistance along 
with inhibiting telomere-independent mechanisms of telomere maintenance in cancer 
cells, making them more universally applicable than conventional telomerase inhibitors.
2, 
10
  
The discrete structures formed by defined numbers of guanosine nucleotides have 
been subsequently termed quadruplexes, a name that is now applied to any structural 
arrangement that incorporates at least two G-quartets (Figure 2)
14
 together with the 
intervening sequences that hold the quartets together. For some years the quadruplex field 
lay dormant, with the widespread belief that these structures were at best artifacts, 
without functional biological significance. It has been only in the past 15 years that this 
picture has been dispelled, with an ever-increasing number of studies indicating a 
diversity of biological roles for quadruplex nucleic acids, at least some of which have 
 
 
4 
 
therapeutic implications. This worldwide increase in activity has resulted in a tenfold 
increase in the number of publications on quadruplexes; with over 400 in 2011. The more 
general interest in quadruplexes has been shown by almost 12,000 citations in 2011 to the 
quadruplex literature.
 1, 15
 
 
Figure 3.  Biological roles and structure of telomeres and the telomerase enzyme. 
Reprinted from reference [6] with permission from the publisher. 
 
The prevalence of G-quadruplex forming-sequences in the promoter regions of 
genes involved in proliferation such as c-myc, c-kit, k-ras, bcl-2 and PDGF-A suggests 
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that it might be possible to use them to artificially regulate transcription of these genes, 
and there is growing evidence that this is achievable. Even though G-quadruplex 
formation has to compete with stable duplex DNA formed at promoter sites, it has been 
shown that G-quadruplexes can be induced under conditions which mimic the 
intracellular environment, and that their formation can have significant biological 
consequences.
3
 Telomerase activity and G4-DNA formation in telomeres are significant 
as they represent potential sites for small molecule drug interactions, in the treatment of 
cancer, which may not have the ill effects of indiscriminate B-DNA binding.  Small 
molecules that can selectively bind to and stabilize these G-DNA structures would 
represent a new class of potential anti-cancer therapeutics. 
16-18
 
2.1 B-DNA Characteristics 
2.1.1 DNA-Interactive Drugs 
Another site in which drugs can interact is with DNA or deoxyribonucleic acid, 
the polynucleotide that carries the genetic information in cells. Because DNA is so vital 
to human functioning, and from the perspective of medicinal chemistry the overall shape 
and chemical structure of DNA found in normal and abnormal cells is nearly 
indistinguishable, drugs that interact with DNA are generally very toxic to normal cells. 
Because the medical term for cancer is neoplasm, anticancer drugs may be referred to as 
antineoplastic agents. Unlike the design of drugs that act on enzymes in a foreign 
organism, there is little that is useful to direct the design of selective agents against 
abnormal DNA. One feature of cancer cells that differentiates them from that of most 
normal cells is that cancer cells undergo a rapid, abnormal, and uncontrolled cell division. 
Genes coding for differentiation in cancer cells appear to be shut off or inadequately 
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expressed, while genes coding for cell proliferation are expressed when they should not 
be. Because these cells are continually undergoing mitosis, there is a constant need for 
rapid production of DNA. Because of the correspondence of normal and abnormal DNA, 
a compound that reacts with a cancer cell will react with a normal cell as well. However, 
because of rapid cell division, cancer cell mitosis can be halted preferentially to that 
found in normal cells where there is sufficient time for the triggering of repair 
mechanisms. Tumor cells, however, are defective in their ability to undergo cell cycle 
arrest or apoptosis in response to DNA damage. Cancer cells that cannot undergo cell 
cycle arrest are sensitive to DNA damaging agents. In general, anticancer drugs are most 
effective against malignant tumors with a large proportion of rapidly dividing cells, such 
as leukemias and lymphomas. Unfortunately, the most common tumors are solid tumors, 
which have a small proportion of rapidly dividing cells.
19
 
2.1.2 Structure of DNA 
 The elucidation of the structure of DNA by Watson and Crick (Figure 1) was the 
culmination of experimental results reported by a large number of scientists over several 
years. All of this data was digested by Watson and Crick, who then proposed that two 
strands of DNA are intertwined into a helical duplex which is held together by specific 
hydrogen bonding between base pairs of adenine with thymine and guanine with cytosine 
(Figure 4) to explain the results of Gulland and Chargar and that there base pairs were 
stacked at 3.4Å distance, as observed in the X-ray photographs. Furthermore, right-
handed rotation between adjacent base pairs by about 36° produces a double helix with 
10 base pairs per turn. A model of the helix was constructed using dimensions and 
confirmations of the individual nucleotides based on the structure of cytidine. The bases 
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are located along the axis of the helix with sugar phosphate backbones winding in an 
antiparallel orientation along the periphery (Figure 1).
 19
 
 
Figure 4.  Sites of alkylation on DNA bases. Reprinted from reference [21] with 
permission from the publisher. 
 
All of the bases of the DNA are on the inside of the double helix, and the sugar 
phosphates are on the outside; therefore, the bases on one strand are close to those on the 
other. Because of this fit, specific base pairing between a large purine base (either A or 
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G) on one chain and a smaller pyrimidine base (T or C) on the other chain are essential. 
Hydrogen bonds between guanines and cytosine or adenine and thymine are more 
effective than any other combination. Therefore, complementary base pairs (also called 
Watson-Crick base pairs) form between guanines and cytokines or adenines and 
thymines only, resulting in a complementary relation between sequences of bases on the 
two polynucleotide strands of the double helix. As you might predict, because there are 
three hydrogen bonds between G and C base pairs and only two hydrogen bonds between 
A  and T base pairs, the former are more stable.
 19
 
 The two glycoside bonds that connect the base pair to its sugar rings are not 
directly opposite each other, and, therefore, the two sugar-phosphate backbones of the 
double helix are not equally spaced along the helical axis (Figure 1). As a result, the 
grooves that are formed between the backbones are not of equal size. The larger groove is 
called the major groove and the smaller one is called the minor groove (Figure 1). One 
side of every base pair faces into the major groove, and the other side faces into the minor 
groove. The floor of the major groove is filled with base pair nitrogen and oxygen atoms 
that project inward from their sugar phosphate backbones toward the center of the DNA. 
The floor of the minor groove is filled with nitrogen and oxygen atoms of base pairs that 
project outward from their sugar phosphate backbones toward the outer edge of the 
DNA.
19
 
2.1.3 Classes of Drugs That Interact with DNA 
In general, there are three major classes of clinically important DNA-interactive 
drugs: reversible binders, which interact with DNA through the reversible formation of 
non-covalent interactions; alkylators, which react covalently with DNA bases; and DNA  
 
 
9 
 
strand breakers, which generate reactive radicals that produce cleavage of the 
polynucleotide strands. It is not yet clear what DNA sequences (genes) should be 
targeted. Also, in traditional cancer chemotherapy significant amounts of DNA damage 
are required to elicit the cell killing that is necessary for effective anticancer drugs. 
19
 
Alkylating agents are a ubiquitous family of reactive chemicals that transfer alkyl 
carbon groups onto a broad range of biological molecules, thereby altering their structure 
and potentially disrupting their function as Lippard et. al showed with cisplatin
20
 (Figure 
5). Alkylating agents are generally unavoidable owing to their abundant presence in the 
 
Figure 5. Structure of the damaged DNA duplex 
environment and within living cells. Major sources of external alkylating agents include 
the constituents of air, water and food, such as biological byproducts (for example, 
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abiotic plant material) and pollutants (for example, tobacco smoke and fuel combustion 
products). Internally, alkylating agents can arise as byproducts of oxidative damage or 
from cellular methyl donors such as S‑adenosylmethionine. Owing to the cytotoxic, 
teratogenic and carcinogenic effects that are caused by alkylation damage, alkylating 
agents pose considerable threats to human health. In spite of this, certain toxic alkylating 
agents are commonly used systemically as chemotherapeutic drugs in cancer patients, 
with the goal of killing cancer cells. Consequently, although alkylating agents can induce 
cancer, they are also used to treat cancer. On the basis of the double-edged properties of 
alkylating agents, a greater understanding of the cellular factors that determine biological 
outcome in response to alkylation damage is particularly relevant for both cancer 
prevention and cancer therapy, in addition to general human health. The biological 
response to alkylating agents can be complex owing to the variety of lesions that are 
introduced by a single alkylating agent in combination with the diversity of cellular repair 
mechanisms and response pathways that can be elicited on alkylation damage.
21
 
2.1.4 DNA Alkylators 
 Alkylating agents react with the ring nitrogens (N) and extracyclic oxygen (O) 
atoms of DNA bases (Figure 1) to generate a variety of covalent adducts that range from 
simple methyl groups to complex alkyl additions. The pattern of DNA lesions generated 
by an alkylating agent depends on the number of reactive sites within the alkylating agent 
(monofunctional versus bifunctional), its particular chemical reactivity (SN1-type versus 
SN2-type nucleophilic substitution) (Scheme 1a), the type of alkyl group addition (methyl 
or chloroethyl and so on) and the DNA substrate (double-stranded or single-stranded). 
Monofunctional alkylating agents contain one active chemical moiety for the 
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modification of a single site in DNA, whereas bifunctional alkylating agents contain two 
reactive groups that can bond to separate DNA bases to form interstrand crosslinks. 
Whereas SN2-alkylating agents mainly target ring nitrogen atoms in DNA bases, SN1-
alkylating agents can modify these nitrogens plus the extracyclic oxygen groups (Figure 
6). Notably, nearly all chemotherapeutic alkylating drugs that are currently used in the 
clinic are SN1-type and they can be either mono-functional or bi-functional (Figure 6).
 21
 
 Owing to the high nucleophilic reactivity of the N7-position of guanine in DNA, 
most monofunctional methylating agents induce the formation of N7-methyl guanine 
(7meG) as the predominant methylation adduct, which accounts for 60–80% of the total 
alkylation lesions in DNA with 3meA being second accounting for 10–20% (Figure 4). 
By itself, 7meG does not possess any mutagenic or cytotoxic properties with 3meA lesion 
being highly cytotoxic. Amongst the oxygen atoms of DNA, the O6-position of guanine 
is a major site of methylation by SN1-type alkylating agents for generating O6-
methylguanine (O6meG) (Figure 4). Even though O‑alkyl lesions are generated to a 
much lesser extent than N‑alkyl adducts, the induction of O6meG lesions by alkylating 
agents is of great biological relevance because O6meG can readily mispair with thymine 
during DNA replication to cause many of the mutagenic and cytotoxic biological effects 
of alkylating agents. Alkylating agents can also modify other nitrogen and oxygen atoms 
in DNA to generate additional toxic and mutagenic lesions. However, these lesions are 
observed at tenfold to 100‑fold lower levels than the lesions mentioned above and 
represent a small proportion of total alkylation adducts.
 21
 
Several monofunctional SN1-methylating agents are currently used as anticancer 
drugs; these include the triazine family of compounds such as dacarbazine, procarbazine 
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and temozolomide, as well as the nitrosourea compound streptozotocin (Figure 6). Owing 
to their chemical reactivity as monofunctional SN1-methylating agents, these  
 
Figure 6.  DNA lesions induced by alkylating agents. Reprinted from reference [21] 
with permission from the publisher. 
 
chemotherapeutic alkylating agents produce substantial levels of 7meG, 3meA and 
O6meG as the primary alkylated DNA adducts. The chloroethylating agents represent 
another major class of monofunctional alkylating agents that react with DNA at a similar 
specificity to SN1-methylating agents except with the addition of a chloroethyl group. 
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Most nitrosourea compounds that are used in the clinic are chloroethylating agents that 
can modify the N7 and O6-positions of guanine to generate chloroethyl adducts (Figure 
6). Importantly, O6-chloroethyl guanine (O6Cl-ethylG) adducts undergo rapid chemical 
rearrangement to react with nearby cytosine bases to generate guanine–cytosine (G–C) 
interstrand crosslinks that are highly cytotoxic.
 21 
Bifunctional alkylating agents have similar reactive properties to monofunctional 
alkylating agents but contain two active moieties that can react with separate bases of  
 
 
Scheme 1. Mechanisms of nucleophilic substitution. a.) Nucleophilic substitution 
mechanism. b.) Mechanism for alkylation of DNA 
 
a.) 
b.) 
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DNA to form interstrand crosslinks in addition to monoadducts (Figure 6). The nitrogen 
mustards and aziridine compounds are two major classes of bifunctional alkylating drugs 
used for cancer treatment that can crosslink DNA through an aziridinium-ring 
intermediate. Nitrogen mustard compounds react readily with N7-guanine and, to a lesser 
extent, with N3-adenine and N7-adenine to form bulky N-monoadducts. These adducts 
can subsequently react with another base to form guanine–guanine (G–G) and guanine–
adenine (G–A) interstrand crosslinks (Figure 6). 
Depending on their position in DNA, the different base adducts that are 
introduced by alkylating agents can compromise genome integrity by inducing 
mutagenesis (thereby promoting cancer induction) and/or by blocking essential biological 
processes such as DNA replication and transcription (which could potentially lead to cell 
death). Moreover, certain lesions can also be processed into clastogenic and cytotoxic 
products that can engage other DNA repair pathways or that can induce programmed cell 
death. It is important to note that other biological molecules are also subject to alkylation 
damage, including RNA, protein, lipids and mitochondrial DNA. Thus, a single 
chemotherapeutic alkylating agent can modify a variety of biological molecules to 
generate a range of lesions that can elicit a number of biological effects.
 21
 
3.1 G-quadruplex Structure 
3.1.1 The G-quadruplex backbone 
The fundamental unit of the G-quadruplex is the G-quartet, which is built from 
the association of four guanine bases in a cyclic motif (Figure 4). Utilizing both  
Hoogsteen hydrogen bonding and Watson–Crick faces, the tetrad is a square shaped unit 
stabilized by eight hydrogen bonds (N1–O6, N2–N7) with the O6 atoms pointing 
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centrally into the ring to form an anionic anti-prismatic bipyramidal cage (Figure 7). The 
planar tetrad can further associate to form extended 3D structures exploiting their large 
aromatic π-surfaces, which are bigger than the Watson-Crick base pairs. The square 
aromatic surface is then further stabilized by association of metal ions that intercalate into 
the central channel (Figure 7), and this difference constitutes the basis for designing G-
quadruplex specific ligands.
5, 22-23 
 
 
Figure 7.  Guanine Base Pairing & Quadruplex Structures. Reprinted from reference 
[14] with permission from the publisher. 
 
3.1.2 Topology for potential G-quadruplex binders 
G-quartets can stack on top of each other to form four-stranded G-quadruplexes 
(Figure 7). These structures exhibit extensive structural diversity and polymorphism 
relative to duplex DNA. In general, structural polymorphism arises mostly from the   
nature of the loop, such as variations of strand stoichiometry, strand polarity, glycosidic 
torsion angle(s), and the location of the loops that link the guanine strand(s). Meanwhile, 
the solution environment, such as the presence of metal ions, ligands, or molecular 
 
 
16 
 
crowding conditions, may also influence the topology of quadruplex.
5
 G-quadruplexes 
can be folded from a single G-rich sequence intra-molecularly (parallel) or by the 
intermolecular association of two (dimeric or bimolecular, antiparallel or parallel) or four 
(tetrameric or tetramolecular, parallel) separate strands.
5, 24
 The telomeric G-quadruplex-
forming sequence structures has been summarized by Ou et al. (see Figure 8).
5
 The 
stacked tetrads remain planar, with a similar rise and twist and the direction (5’ to 3’) that 
the phosphodiester backbone runs can vary. In duplex DNA and RNA, an anti-parallel 
arrangement is required, while quadruplexes can accommodate any combination of 
directions, giving rise to both parallel and anti-parallel alignments
22
 (Figure 9a). For 
example, two intramolecular G-quadruplex structures have been identified from the 
human telomeric sequence as the basket-type and propeller-type, depending on the 
incubation conditions (Figure 9).
24 
 
Figure 8. G4-DNA topologies and diversities. Reprinted from  reference [6] with 
permission from the publisher. 
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Variations in strand polarity also affect the location of the linkers, or loops 
between G-rich segments. As shown in Figure 9a, parallel G-strands require a connecting 
loop to link the bottom G-tetrad with the top one, leading to propeller-type loops. In 
general, the sequence and size of the loops play an important role in determining the 
topology and stability of quadruplexes. In addition, loop residues can themselves form 
stacking and hydrogen bonding interactions, further stabilizing (or destabilizing) G- 
quadruplex folds, while longer linker lengths favor antiparallel backbone alignments, 
which may also contain guanine residues that could be expected to form part of a guanine 
tetrad.
5
 A recent molecular dynamics simulation has revealed that the sequences of the 
connecting loops in quadruplexes are the major contributors to quadruplex flexibility and 
are the potential sites for drug binding.
 5, 16-18, 22-23, 25
 
The central coordinated charged cavity can accommodate a variety of metal 
cations of different radii that strongly influences not only the final folded topology of the 
stacked quadruplex but also its stability. The metal ion stabilizing influence is linked to 
the increasing radii from Li+ < Na+ < K+ with potassium being optimal, and 
dramatically increasing G-quadruplex stability. The hole between G-tetrads is well suited 
to coordinating cations of this size because the two planes of tetrads are lined by eight 
carbonyl O6 atoms (with strong negative electrostatic potential) that create a central 
negatively charged channel inside the G-tetrad stack (Figure 9b).
5, 16-18, 22-25
 
In solution, many quadruplex-forming sequences adopt multiple folding 
topologies depending on the length of individual G-quartets, loop composition and size, 
and the type of cation. It has been reported that human genes contain as many as 376,000 
 
 
18 
 
quadruplex-forming sequences.
26
 Databases used in screening and identifying G-
quadruplex structures are very common. With the increasing number of quadruplexes 
 
 
Figure 9. Basic G-Quadruplex building blocks. Reprinted from reference [6] with 
permission from the publisher. 
 
reported in genomic studies, drug design must be directed not only to differentiating 
between duplex and quadruplex DNA species, but also to recognizing different 
quadruplex species. The area of G-quartets, loop regions, groove dimensions, and the 
negative electrostatic potential of the anionic backbone and the central channel of G-
quadruplexes are critical elements that need to be considered in order to improve the 
binding selectivity of drug candidates.
5
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4.1 G-quadruplex Binding Ligands 
4.1.1 Quadruplex DNA Small Molecule Interactions 
Small molecules that induce the formation of, and/or selectively bind to, G-
quadruplex structures are of interest for development as potential therapeutic agents, 
particularly in the anticancer therapeutic area. Of the quadruplex binding molecules 
identified to date, many are based on core functionalized polycyclic heteroaromatic 
systems such as acridines, anthraquinones, perylenes or porphyrins (Figure 10). A few of 
these have been shown to produce G-quadruplex-related biological effects even though 
their physicochemical features are conventionally non-drug-like. A common approach to 
G-quadruplex ligand design involves taking these relatively large aromatic ring systems 
as a starting-point on the basis that they can interact with the terminal G-quartets of a 
quadruplex through π–π interactions (end-stacking). Thus, the first small molecule 
reported to bind to G-quadruplex DNA was an anthraquinone derivative. Following this, 
molecules containing similar structural motifs such as fluorenones and acridines were 
described. As aromatic groups alone are insufficient to confer high binding affinity, and 
their hydrophobicity reduces water solubility, they have frequently been functionalized 
with one or more cationic side chains to improve solubility and enhance potential 
bonding interactions with backbone phosphates and functional groups in the unique loops 
and grooves found in G-quadruplex structures.
3, 27
 
In addition, several G-quadruplex-targeting ligands designed to date have shape 
characteristics that minimize duplex DNA interaction. This design strategy is apparent in  
the acridine derivative BRACO-19, the first synthetic G-quadruplex ligand to have 
significant selectivity compared to duplex DNA. Other polycyclic G-quadruplex-binding 
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ligands include TMPyP4 (a cationic porphyrin), telomestatin (a cyclic oxazole-containing 
natural product from Streptomyces anulatus), and RHPS426 (a polycyclic acridine)  
 
Figure 10. Quadruplex-DNA binding molecules 
 
(Figure 6). The large planar surfaces of these compounds, their high molecular weights 
(600 or above) and lipophilicity, and (for some) their significant charge and poor water 
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solubility indicate that they are mostly non-drug-like and deviate from the Lipinski Rule 
of Five in terms of their potential for oral bio-availability.
3 
More recent reports have 
demonstrated that non-conjugated compounds that are synthetically more accessible than 
telomestatin can have potency against telomerase and quadruplex selectivity. Many 
quadruplex-binding ligands have been reported subsequently, although relatively few 
have been evaluated in cell-based assays, or even with reliable in vitro telomerase 
assays.
4, 27
 To date, quarfloxin (Figure 10) is the only G-quadruplex ligand from the large 
number that have been developed to have progressed to clinical evaluation.
3
 
G4-DNA binding molecules have been the subject of much study in the new 
millennium with many examples showing a high degree of selectivity and binding 
stability.
28-33
  However, daunomycin (Figure 10) is already a compound used in general 
medical practice to treat cancer and has appreciable G4-DNA binding affinity.  This data 
suggests that the antitumor activity of daunomycin may in fact be due, in some part, to 
quadruplex stabilizations in genomic DNA. 
 It is proposed that designing the optimal G4-DNA binder must also contain some 
mimic of a bio-molecule (e.g. peptide bonds) so as to minimize recognition as an antigen, 
quick metabolism, and excretion from the body before it can exert its function.  Because 
of the compact nature of duplex DNA a G4-DNA binding ligand would need to be pre-
organized so that unfavorable steric interactions would keep the required large planar 
group from intercalating between the base pairs.  Figure 11 illustrates the isoxazole 
systems, containing an anthracene or anthrone ring system with a hydrogen bond 
acceptor ethyl isoxazole ester, which could serve the purpose addressing all of the 
important factors (i.e. pre-organization, hydrogen bond acceptor/donor, and small size).  
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Figure 11. Combining functionalities to form a selective G4-DNA ligand.  
 
4.1.2 Structural Features of a non-B-DNA binder 
The anthracene isoxazole ester system (AIE) (Figure 11) was designed so as not 
to intercalate B-DNA because of the small distance between the isoxazole and anthracene 
moieties. AIE was designed to mimic the behavior of guanines and stabilize or induce the 
G-quadruplex structure, which in turn can inhibit telomerase activity. The essential 
pharmacophore for telomerase inhibition is a large aromatic core that favors planar π-π 
stacking interactions with the G-tetrads. Positively charged side chains that interact with 
the DNA grooves, can exploit the central electronegative channel to enhance binding. 
Electrostatic interactions between ligand side chains and DNA phosphates play a major 
role in the formation and stabilization of G-quadruplex structures and in selecting its 
topology; so the presence of a cationic center on side chain is favorable for optimal 
electrostatic interactions with negative charges on the phosphate backbone of DNA. The 
size of the side chain is also important, and small tether length has better inhibitory 
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activity. Existence of an atom which can form a hydrogen bond is favorable, especially 
an oxygen atom..
2
 
Also, Neidle had previously shown that there were several possible binding 
modes (Figure 12) for amidoanthracne-9, 10-diones to quadruplex DNA based on  
 
Figure 12.  G-quadruplex small molecule stabilization binding modes. Reprinted 
from reference [54] with permission from the publisher. 
 
substitution using molecular modeling,
33-35
 stopped-flow kinetics,
36
 thermal DNA 
melting,
35
 and X-ray crystalography.
35
  Hurley showed that the porphyrns 5,10,15,20-
tetra-(N-methyl-2-pyridyl)porphine (TMPyP2) and 5,10,15,20-tetra-(N-methyl-2-
pyridyl)porphine (TMPyP4) (Figure 10), bind G-quadruplex structures externally atop the 
G-tetrad.
37
  Furthermore, Hurley and Neidle described in a review how quindoline and 
Berberine (related plant alkaloid) are classic G-quadruplex binding agents with their 
derivatives showing significant anti-proliferative properties in cancer cell lines; as well 
as, the two current standards in quadruplex binding: telomestatin and tri-substituted 
isoalloxazines.
14
 Given these findings we felt the next step was to use computer based 
molecular modeling to determine which mode of binding best suited the AIE system.  
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5.1 10-Methoxy anthracene isoxazole ester synthesis 
 Scheme 1 outlines the modified synthesis method from the oxime used by Natale 
and coworkers 
38-40 
to generate anthracene isoxazole ester 1.  Initial bromination of 2 was 
successful in methylene chloride with a slight modification from Cakmak and 
coworkers
41
. Subsequent methylation of 3 was achieved with the addition of a 1.2-fold 
excess of sodium methoxide in situ in warm DMF yielding 4 in good yields. 
 
Scheme 2.  Method for the formation of anthracene isoxazole ester 1 
  Oxime formation from the aldehyde of 4 with hydroxyl amine hydrochloride and 
sodium acetate in refluxing DMF afforded the oxime 5.  Formation of the oximinoyl 
chloride intermediate 6 was performed using recrystallized N-Chlorosuccinamide (from 
benzene) and CHCl3 at room temperature (yield not calculated).  Finally, 6 was reacted 
with triethylamine and ethyl acetoacetate in absolute ethanol to give the final product 1 in 
92% yield after two steps. 
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6.1 Anthrone isoxazole ester 
Scheme 2 outlines the anthrone synthesis combined with the method used by 
Natale and coworkers
40
 to generate symmetrical anthrone isoxazole ester 13. Subsequent 
oxime formation from the aldehyde 8 was achieved with the addition of a 2.0 eq. excess 
hydroxylamine hydrochloride and a 3.5 eq. excess of sodium acetate in THF:EtOH:H2O 
until the no slurry was observed yielding 9. 
Scheme 3.  Method for the formation of anthrone isoxazole ester 13 
  Formation of the oximinoyl chloride intermediate 10 was performed using 
recrystallized N-Chlorosuccinamide (from benzene) and dry CHCl3 at 45
o
C (yield not 
calculated).  Oximidoyl chloride 10 was reacted with sodium ethoxide and ethyl 
acetoacetate in absolute ethanol to give the product 11 in great yields after two steps. The 
subsequent chlorination of 11 was achieved with a slight modification from the procedure 
of Natale and coworkers
40
.  Finally, another chlorination reaction with NCS in DMF gave 
the final product 13.  
 
 
26 
 
The regiochemistry of the final product 13 was determined by 2D correlation 
spectroscopy or HSQC (Heteronuclear Single Quantum Coherence). Figure 13 illustrates 
an example of how the proton assignments and regiochemistry were made from a HSQC 
experiment of anthrone product 13. The numerical labels such as 8.31, 182.5, and 0.05 
indicate protons correlated, carbons correlated and intensity. The peri-aryl protons H-9 & 
H-19 are easily spotted at ppm 7.26 by their strong J2 coupling and chemical shift which 
have a strong correlation to the tertiary carbon at ppm 62. It is clear that H-12 and H-16 
are down field at ppm 8.31 correlating to the carbonyl carbon ppm 182.  
7.1 Anthrone isoxazole ester crystal structure 
The crystal structure of ethyl 3-(9-chloro-10-oxo-9, 10-dihydroanthracen-9-yl)-5-
methylisoxazole-4-carboxylate (13) was obtained. It possesses similar bond lengths and 
angles as the previously reported isoxazole ester, ethyl 3-(10'-chloro-9'-anthracenyl)-5-
methyl-4-isoxazolecarboxylate. The anthrone is virtually planar, and adopts a shallow 
boat conformation, as evidenced by the absolute sum of the six intra- B-ring dihedral 
angles (40.9081°). The compound adopts a conformation wherein the isoxazole ring is 
roughly orthogonal (torsion angle: C60 C56 C62 C63, 67.0°) to the anthrone ring (see 
Figure 14) with the isoxazolyl ester carbonyl O(7) being located within 3.3Å of the 
anthrone carbon C(31). Furthermore, in the unit cell the anthrone H(6) of one molecule of 
the title compound is within 3.3Å of C(22) of the second molecule at a dihedral angle of 
~30
o
, consistent with an edge-to-face π-stacking interaction. This conformation could be 
a vital factor in the study of the binding of this species in the drug-DNA complex in 
further research.  
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Figure 13:  HSQC of 13, shows proton shift, carbon shift, and correlation intensity. 
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Figure 14:  ORTEP diagram of 13.  
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8.1 Experimental Section 
All starting chemicals were purchased from Aldrich Chemical Company and used 
without any further purification unless otherwise indicated. Solvents were reagents grade 
and dried just prior to use by standard methods. Melting points were determined in open 
capillary tubes on a Melt-Temp apparatus and are uncorrected. High resolution mass 
spectra (HRMS) were obtained using a Micromass electrospray ionization (ESI)/time-of-
flight mass spectrometry (LCTOF). NMR spectra for preliminary identification of 
products were collected on a Bruker AC200 (UltraShield™ 400MHz) using X-Win NMR 
(3.1). Mass spectrometer samples were introduced using a Waters model 2690 
separations module HPLC fitted with a C-18 reversed phase column (2.1 mm i.d., 5 cm).  
Flash chromatography was performed using Sorbent Technologies standard silica gel (60 
Å) with reagent grade solvents using in house compressed air. 
8.1.1 Method of 10-methoxy anthracene isoxazole ester formation 
To a suspension of 2 (4.175g, 20.244mmol; Sigma-Aldrich, 97%) in methylene 
chloride (120mL) was added Br2 (1.1 eq., 1.2mL, 23.428mmol) diluted in methylene 
chloride (5mL) drop wise over 5 minutes. The reaction was covered with septa and guard 
column (charged with CaCl2 and NaOH(s)) and allowed to stir at 63°C until TLC showed 
no starting material remained (ca. 5 hours). Once the solution reached room temperature, 
25g Na2SO3 in 200mL H2O was added to neutralize excess Br2. The solution was then 
transferred to a separatory funnel, washed with 50mL metheylene chloride and the 
organic layer extracted and dried with sodium sulfate and concentrated under reduced 
pressure to yield 3 (Rf=0.34, 10:1 Hex/EtOAc, Figure 15). Recrystallized from 
chloroform/hexanes. 
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10-Bromoanthracene-9-carbaldehyde (3). (83%)
 1
H NMR(CDCl3) δ  11.52 (s, 1H), 
8.90-8.93 (m, 2H), 8.69-8.71 (m, 2H), 7.64-7.74 (m, 4H). 
13
C NMR (CDCl3)  δ 193.28, 
131.94, 131.82, 130.29, 129.02, 128.91, 128.29, 128.29, 127.47, 127.40, 125.70, 123.84. 
mp 205-208°C. Spectral data are in accord with those reported previously.
42-43
 
The brominated aldehyde 3 (0.150g, 0.5261mmol) was taken up in 2mL of DMF 
(dried over sieves) under a nitrogen atmosphere.  Freshly distilled methanol (1.2 eq., 
0.03mL) was added via syringe. Sodium hydride (1.2 eq., 0.0253g) was added with a 
water condenser. The solution was allowed to stir at 60°C for 3.5 hours under an argon 
atmosphere. Once the solution cooled to room temperature, 50mL DI H2O and 50mL 
diethyl ether was added and allowed to stir for 15 minutes. The solution was transferred 
to a separatory funnel and washed with 50mL diethyl ether. The combined organic layers 
were washed with 50mL Brine, dried over sodium sulfate and concentrated under 
reduced pressure. The solid was taken up in minimal methylene chloride and ran on a 
prepared hexanes silica column in 12:1 (Hexanes:EtOAc) until all desired product 4 was 
collected (Figure 16). 
10-Methoxyanthracene-9-carbaldehyde (4). (85%) 
1
H NMR (CDCl3) δ 11.49 (s, 1H), 
9.09 (d, J=9.03, 2H), 8.42 (d, J=8.66 Hz, 2H), 7.70-7.74 (m, 2H), 7.58-7.62 (m, 2H), 4.22 
(s, 3H).
 13
C NMR (CDCl3)  δ 191.93, 159.18, 134.12, 133.89, 129.34, 127.23, 125.60, 
124.21, 123.96, 123.11, 121.17, 63.96. MS (EI) m/z  236 (22.37, M+), 237(100, M+1), 
238 (18.80, M+2). (Rf=0.46 4:1:1 Hex/EtOAc/DCM).  
To a suspension of 4 (0.1659g, 0.6302mmol) in 200 proof ethanol (23mL) was 
dissolved hydroxylamine hydrochloride (2.5eq, 0.1095g, 1.58mmol) and pyridine (20eq, 
1mL, 12.4mmol) The reaction was covered with a septa and water condenser and let 
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reflux (ca. 80°C) for 2 days under an argon atmosphere. The solution was first 
concentrated under reduced pressure then transferred to a separatory funnel and washed 1 
x 50mL 1N HCl (cold) and the combined aqueous layers washed 2 x 20mL CH2Cl2, dried 
over sodium sulfate, filtered, and the solvent removed under vacuum. The solid was then 
chromatographed on a prepared hexanes silica column starting with 8:1:1 
Hex/EtOAc/DCM, 4:1:1, and finally 2:1:1 until desired product 5 was all collected 
(Figure 17). 
10-Methoxyanthracene-9-carbaldehyde oxime (5): (79%) 
1
H NMR (CDCl3) δ 9.20 (s, 
1H), 8.45-8.46 (m, 2H), 8.36-8.38 (m, 2H), 7.53-7.60 (m, 4H), 4.17 (s, 3H).
 13
C NMR 
(CDCl3) δ 154.22, 148.95, 131.20, 126.90, 125.36, 125.29, 124.29, 122.72, 119.83, 
63.45. MS (EI) m/z 234 (100, M-H2O), 235 (28.54, M-H2O)
+
, 252 (38.87, M+1). 
(Rf=0.34, 4:1:1 Hex/EtOAc/DCM).  
The starting oxime 5 (0.0905g, 0.3601mmol) was taken up in 10mL of 
chloroform at room temperature, to which the solution was added Et3N (1.23eq, 0.045g) 
and recrystallized NCS (1.45eq, 0.0697g, .52198mmol) over 5 minutes.  The solution was 
allowed to stir at room temperature under argon for 2 hours.  The organic layer was 
washed with 1 x 100mL DI H2O, then the aqueous layer washed 1 x 20mL CHCl3, dried 
with sodium sulfate, filtered, and the solvent removed under reduced pressure to yield 6. 
The intermediate 6 was purified only through extractive isolation using water and CHCl3 
and taken on to the next reaction as is. To a solution of 6 in absolute ethanol (20mL) was 
added 1.75 equivalents of ethyl acetoacetate (0.0741g, 0.6314mmol) and 1.91eq. Et3N 
(0.0696g, 0.6878mmol). The mixture was allowed to stir at 40°C under argon for 30 
hours until TLC in 4:1:1 Hex/EtOAc/DCM revealed all nitrile oxide had been consumed.  
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Finally, the ethanol was removed via rotary evaporation and the solid dissolved in CHCl3, 
washed 2 x 50mL Brine, and the aqueous layer washed 1 x 20mL CHCl3, dried sodium 
sulfate, and concentrated under reduced pressure. The solid was then chromatographed 
using 1:1 Hex/EtOAc, then 1:2 and flushed with EtOAc until all desired product 1 
(Figure 18) was collected. 
N-hydroxy-10-methoxyanthracene-9-carbimidoyl chloride (6): Was not purified, 
carried on through in situ procedure only. 
1
H NMR(400 MHz, CDCl3) δ 8.36 (d, J=8.78 
Hz, 2H), 8.31 (d, J=8.78, 2H), 7.70 (t, J=15.06, 7.40 Hz, 2H), 7.60 (t, J=15.31, 8.28 Hz, 
2H), 4.20 (s, 3H). 
Ethyl 3-(10-methoxyanthracen-9-yl)-5-methylisoxazole-4-carboxylate (1). 32%. 
(Rf=0.17 1:2 Hex/DCM, Rf=0.49 4:1:1 Hex/EtOAc/DCM). 
1
H NMR(400 MHz, CDCl3) 
δ 8.37 (d, J=8.77 Hz, 2H), 7.65 (d, J=8.53 Hz, 2H), 7.51 (t, 2H), 7.43 (t, 2H), 4.20 (s, 
3H), 3.71 (q, J=7.15 Hz, 2H), 2.93 (s, 3H), 0.35 (t, J=7.15 Hz, 3H). 
8.1.2 Method of anthrone isoxazole ester formation 
To a suspension of 8 (4.0g, 19.39mmol; Sigma-Aldrich, 97%) in THF: Ethanol: 
H2O (54mL: 27mL: 27mL) was dissolved sodium acetate (3.5 eq., 5.57 g, 67.89mmol) 
and hydroxylamine hydrochloride (2eq, 2.69g, 38.71mmol). The reaction was covered 
with a septa and let stir at room temperature until TLC showed no starting material 
remained (ca. 49 hours). The solution was then transferred to a separatory funnel and 
washed 4 x 200mL Brine and the combined aqueous layers washed 2 x 50mL CHCl3, 
dried over sodium sulfate, filtered, and the solvent removed under vacuum to yield 9 
(Figure 19). 
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Anthracene-9-carbaldehyde oxime (9). 99%. (Rf=0.53 4:1:1 Hex/EtOAc/DCM), 
1
H 
NMR (CDCl3) δ 9.22 (s, 1H), 8.51 (s, 1H), 8.42 (d, J=8.66 Hz, 2H), 8.03 (d, J=8.16 Hz, 
2H), 7.50-7.59 (m, 4H). 
13
C NMR (CDCl3) δ 148.98, 131.30, 130.21, 129.35, 128.86, 
128.81, 126.78, 126.42, 125.39, 124.97, 123.64. 
The starting oxime 9 (4.667g, 21.09mmol) was taken up in 120mL of chloroform 
at room temperature, to which a solution of pyridine (10mol%, 2.00mL) and 
recrystallized NCS (1.1eq, 3.098g, 23.20mmol).  The solution brought to 45ºC for 3.5 
hours then cooled to room temperature.  The organic layer was washed with 4 x 200mL 
Brine and 2 x 150mL H2O, then the aqueous layer washed 2 x 150mL CHCl3, dried with 
sodium sulfate, filtered, and the solvent removed under reduced pressure to yield 10. The 
intermediate was purified only through extractive isolation using brine and CHCl3 and 
taken on to the next reaction as is. To a solution of 10 in absolute ethanol (100mL) was 
added 1.4 equivalents of ethyl acetoacetate (3.8425g, 29.53mmol). In a separate round 
bottom was added 50mL absolute ethanol and 1.018g Na(s). Once the sodium 
dissociation had completed, the warm solution was added to the nitrile oxide and the 
mixture was allowed to stir at room temperature under argon for 21.5 hours until TLC in 
4:1 Hex/EtOAc revealed all 10 had been consumed.  Finally, the ethanol was removed 
via rotary evaporation and the solid dissolved in CHCl3, washed 4 x 200mL Brine, and 
the aqueous layer washed 2 x 150mL CHCl3, dried sodium sulfate, and concentrated 
under reduced pressure. The solid was then chromatographed using 4:1 Hex/EtOAc to 
give desired product 11 (Figure 20). 
N-hydroxyanthracene-9-carbimidoyl chloride (10): Was not purified, carried on 
through in situ procedure only 
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Ethyl 3-(anthracen-9-yl)-5-methylisoxazole-4-carboxylate (11). 93%.
1
H NMR (400 
MHz, CDCl3) δ 8.59 (s, 1H), 8.06 (d, J=7.91, 2H), 7.66 (d, J=8.16 Hz, 2H), 7.41-7.50 (m, 
4H), 3.70 (q, J=7.15 Hz, 2H), 2.93 (s, 3H), 0.33 (t, J=7.15 Hz, 3H). 
13
C NMR (CDCl3) δ 
176.16, 161.52, 160.44, 131.01, 130.82, 128.64, 128.45, 126.25, 125.44, 125.21, 122.75, 
111.37, 60.02, 13.41, 12.80. Spectral data are in accord with those reported previously
38-
39
. 
Compound 11 (0.300g, 0.905mmol) was taken up in 10mL DMF to which was 
added a solution over 10 minutes of N-Chlorosuccinimide (NCS) (1.2eq, 0.1461g, 
1.094mmol) dissolved in 5mL DMF.  The solution was brought to 43ºC and let stir for 4 
hours whereupon the solution was poured into 50mL ice/water which was allowed to stir 
for 1 hour with the product 12 (Figure 21) precipitating out. Product was filtered and 
washed with 2 x 25mL DI water. 
Ethyl 3-(10-chloroanthracen-9-yl)-5-methylisoxazole-4-carboxylate (12). 96%.
1
H 
NMR (400 MHz, CDCl3) δ 8.59 (d, J=8.91 Hz, 2H), 7.59-7.66 (m, 4H), 7.46-7.50 (m, 
2H), 3.72 (q, J=7.15 Hz, 2H), 2.93 (s, 3H), 0.39 (t, J=7.15 Hz, 3H). 
13
C NMR (CDCl3) δ 
176.29, 161.28, 160.15, 131.13, 131.00, 128.30, 126.67, 126.52, 125.84, 125.04, 122.60, 
111.43, 60.15, 13.43, 12.91. Spectral data are in accord with those reported previously
38
.  
The chlorinated anthracene 12 (0.3312g, 0.905mmol) was taken up in 5mL DMF 
to which was added a solution over 10 minutes of N-Chlorosuccinimide (NCS) (1.2eq, 
0.1451g, 1.087mmol) dissolved in 5mL DMF.  The solution was brought to 30ºC and let 
stir for 43 hours whereupon the solution was poured into 50mL ice/water which was 
allowed to stir for 1.5 hours with the product precipitated out. Product was filtered and 
washed with DI water. The solid was dissolved in minimal CH2Cl2 and placed on a wet 
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silica column prepared with hexanes. The solvent polarity increased using a stepwise 
elution of 10:1, 6:1, and finally 4:1 until all 13 (Figure 22) was collected.  
Ethyl 3-(9-chloro-10-oxo-9,10-dihydroanthracen-9-yl)-5-methylisoxazole-4-
carboxylate (13). 29%, (Rf=0.28, 4:1 Hex/EtOAc), 
1
H NMR(CDCl3) δ 8.38 (dd, J=1.38, 
7.65 Hz,  2H), 7.51-7.61 (m, 4H), 7.34 (dd, J=1.13, 7.91 Hz,  2H), 3.56 (q, J=7.15 Hz, 
2H), 2.70 (s, 3H), 0.65 (t, J=7.03 Hz, 3H);  
13
C NMR(CDCl3)  δ 182.58, 178.50,162.69, 
159.76, 142.41, 133.92, 129.85, 129.13, 127.84, 127.58, 107.92, 62.51, 60.43, 13.78, 
13.47. MS (EI) m/z 346(100, M-Cl), 347(28.33, M-Cl)
+
, 348(8.42, M-Cl)
+2
.  
9.1 Future Direction 
Many high affinity ligands have been synthesized and studied in previous reports 
but it is proving elusive to structurally determine ligand interactions in a routine manner. 
Currently the application of crystallographic techniques is providing us with the most 
comprehensive picture of ligand binding interactions; however the validity of the model 
is in some ways compromised by crystal packing forces within a crystalline lattice. Even 
within these constraints, it is clear that the stacked G-quadruplex core remains intact with 
little scope for the intercalation of planar ligands.  The diverse ranges of G-quadruplex 
forming sequences identified and characterized appear to be very diverse, folding almost 
exclusively as parallel stranded motifs, thereby limiting the diversity required for 
selective targeting. However, although restricted in topology, the G-quadruplex forming 
sequences will still contain sequence variability in connecting loops, thus providing new 
interaction surfaces and unexpected platforms for interaction. As always, there will be a 
need for current (and newly discovered) G-quadruplexes to be validated in terms of 
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structure and (more importantly) biological role, before effort is applied to finding 
suitable therapeutic agents.  
While Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADME-Tox) is a 
very important part of medicine design the desired biological target should be of primary 
concern when considering design and this has been seriously addressed in the design of 
the AIE series.  However, possibly one of the most important points in designing a small 
molecule drug is the chirality of the target biomolecule or system.  The  
 
Figure 15.  Axial Chiral Anthracene Isoxazole Ester 
 
idea of using chiral small molecules for the treatment of mammalian diseases is not new, 
however, in the case of cancer chemotherapeutics chirality has only recently gained some 
consideration.
44-45
  Chaires and coworkers demonstrated that (+) and (-) enantiomers of 
daunorubicin, for which the (+) enantiomer is a known and potent anti-tumor agent 
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currently used in general medical practice, selectively bind to different forms of DNA,  
B-DNA (Right handed helical) and Z-DNA (Left handed helical) respectively.
46
  The 
inherent chirality of duplex DNA, RNA, and protein α-helices makes these biological 
structures ideal targets for chiral small molecules ligands that bind selectively.  
Quadruplex DNA structures are right handed helical therefore an antitumor molecule that 
would bind selectively to this system must possess the correct element of chirality. 
 It is proposed that adding an axis of chirality to one of the active compounds in 
the AIE series would produce an atropoisomer that should have selectivity for right or left 
handed helical DNA based on Chaires findings.  In addition, functionalization of the 
anthracene, which has some related human toxicity, to somewhat resemble the major 
metabolite of anthracene would provide for better bioavailability and decrease the 
molecule's potentially toxic character (Figure 15).  Though the new system may fall 
outside of the Lipinski range it has been shown that the AIE series is also highly active 
and therefore the methyl pyrrole can be removed to test the Lipinski prediction.  The 
outcome of such a comprehensive study of functionality, ADME-Tox, and Chirality for 
this AIE series of compounds, as they pertain maximum efficacy in tumor cell 
suppression and biomolecule selectivity could be a novel class of antitumor agents that 
have little or no side effects.  The isoxazole functionality establishes not only a pre-
organized system for SAR exploration it is the biological handle that is the foundation of 
many medicines used in general medical practice today, and therefore should be a potent 
contender in the pool of small molecule antitumor agents.
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Figure 16. NMR spectrum of 10-Bromoanthracene-9-carbaldehyde 
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Figure 17. NMR spectrum of 10-Methoxyanthracene-9-carbaldehyde 
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Figure 18. NMR spectrum of 10-Methoxyanthracene-9-carbaldehyde oxime 
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Figure 19. NMR spectrum of Ethyl 3-(10-methoxyanthracen-9-yl)-5-
methylisoxazole-4-carboxylate 
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Figure 20. NMR spectrum of Anthracene-9-carbaldehyde oxime 
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Figure 21. NMR spectrum of  Ethyl 3-(anthracen-9-yl)-5-methylisoxazole-4-
carboxylate 
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Figure 22. NMR spectrum of Ethyl 3-(10-chloroanthracen-9-yl)-5-methylisoxazole-
4-carboxylate 
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Figure 23. NMR spectrum of  Ethyl 3-(9-chloro-10-oxo-9,10-dihydroanthracen-9-
yl)-5-methylisoxazole-4-carboxylate 
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Figure 14. 
 
Experimental details 
Crystal data 
Chemical formula C43H33Cl2NO8 
Mr 762.60 
Crystal system, space group Triclinic, P1 
Temperature (K) 100 
a, b, c (Å) 10.014 (18), 12.57 (2), 14.97 (3) 
α, β, γ (°) 78.09 (6), 73.36 (3), 89.01 (3) 
V (Å
3
) 1765 (6) 
Z 2 
Radiation type ?, λ = 0.71073 Å 
µ (mm
−1
) 0.24 
Crystal size (mm) 0.20 × 0.20 × 0.20 
Data collection 
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Diffractometer ? 
Absorption correction Multi-scan  
SADABS V2012/1 (Bruker AXS Inc.) 
Tmin, Tmax 0.87, 0.95 
No. of measured, 
independent and 
observed [I > 2σ(I)] 
reflections 
21846, 8589, 6877  
Rint 0.030 
(sin θ/λ)max (Å
−1
) 0.682 
Refinement 
R[F
2
 > 2σ(F
2
)], wR(F
2
), S 0.039, 0.109, 1.11 
No. of reflections 8589 
No. of parameters 491 
No. of restraints 0 
H-atom treatment H atoms treated by a mixture of independent and 
constrained refinement 
(Δ/σ)max 0.530 
Δρmax, Δρmin (e Å
−3
) 0.45, −0.22 
Computer programs: SAINT V8.27B (Bruker AXS Inc., 2012), SHELXS97 (Sheldrick, 
2008), SHELXL97 (Sheldrick, 2008). 
Computing details  
Cell refinement: SAINT V8.27B (Bruker AXS Inc., 2012); data reduction: SAINT V8.27B 
(Bruker AXS Inc., 2012); program(s) used to solve structure: SHELXS97 (Sheldrick, 
2008); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008).  
Experimental (I) 
Crystal data 
C43H33Cl2NO8 Z = 2 
Mr = 762.60 F(000) = 792 
Triclinic, P1 Dx = 1.436 Mg m
−3
 
a = 10.014 (18) Å ? radiation, λ = 0.71073 Å 
b = 12.57 (2) Å 
Cell parameters from 9917 
reflections 
c = 14.97 (3) Å θ = 2.2–28.8° 
α = 78.09 (6)° µ = 0.24 mm
−1
 
β = 73.36 (3)° T = 100 K 
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γ = 89.01 (3)° Prism 
V = 1765 (6) Å
3
 0.20 × 0.20 × 0.20 mm 
Data collection 
Detector resolution: 8.3333 pixels 
mm
-1
 
Rint = 0.030 
Absorption correction: multi-scan  
SADABS V2012/1 (Bruker AXS 
Inc.) 
θmax = 29.0°, θmin = 1.5° 
Tmin = 0.87, Tmax = 0.95 h = −13→13 
21846 measured reflections k = −17→16 
8589 independent reflections l = −20→20 
6877 reflections with I > 2σ(I)  
Refinement 
Refinement on F
2
 
Primary atom site location: 
structure-invariant direct methods 
Least-squares matrix: full 
Secondary atom site location: 
difference Fourier map 
R[F
2
 > 2σ(F
2
)] = 0.039 
Hydrogen site location: inferred 
from neighbouring sites 
wR(F
2
) = 0.109 
H atoms treated by a mixture of 
independent and constrained 
refinement 
S = 1.11 
w = 1/[σ
2
(Fo
2
) + (0.060P)
2
]  
where P = (Fo
2
 + 2Fc
2
)/3 
8589 reflections (Δ/σ)max = 0.530 
491 parameters Δρmax = 0.45 e Å
−3
 
0 restraints Δρmin = −0.22 e Å
−3
 
Special details 
Refinement  
Refinement of F
2
 against ALL reflections. The weighted R-factor wR and goodness of fit 
S are based on F
2
, conventional R-factors R are based on F, with F set to zero for 
negative F
2
. The threshold expression of F
2
 > σ(F
2
) is used only for calculating R-
factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors 
based on F
2
 are statistically about twice as large as those based on F, and R- factors based 
on ALL data will be even larger.  
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Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å
2
) 
 x y z Uiso*/Ueq 
Cl1 0.39467 (4) −0.13787 (3) 0.41774 (3) 0.01734 (10) 
Cl2 0.89937 (4) 0.66479 (3) 0.42670 (3) 0.01629 (9) 
C1 0.35916 (16) −0.16673 (12) 0.21644 (11) 0.0170 (3) 
H1 0.2771 −0.2021 0.2618 0.02* 
C2 0.41980 (16) −0.20648 (13) 0.13527 (11) 0.0194 (3) 
H2 0.3805 −0.2701 0.1259 0.023* 
C3 0.53801 (16) −0.15387 (13) 0.06732 (11) 0.0190 (3) 
H3 0.5781 −0.1805 0.011 0.023* 
C4 0.59699 (16) −0.06301 (13) 0.08184 (11) 0.0169 (3) 
H4 0.6778 −0.0272 0.0353 0.02* 
C5 0.59779 (16) 0.20976 (12) 0.27859 (11) 0.0156 (3) 
H5 0.6837 0.241 0.2352 0.019* 
C6 0.53337 (16) 0.25573 (12) 0.35502 (11) 0.0176 (3) 
H6 0.5753 0.3179 0.3648 0.021* 
C7 0.40673 (17) 0.21076 (13) 0.41786 (11) 0.0186 (3) 
H7 0.3609 0.2435 0.4697 0.022* 
C8 0.34743 (16) 0.11879 (12) 0.40524 (11) 0.0161 (3) 
H8 0.261 0.0884 0.4485 0.019* 
C9 0.35237 (15) −0.03612 (11) 0.32323 (10) 0.0119 (3) 
C10 0.60597 (15) 0.07311 (12) 0.17908 (10) 0.0136 (3) 
C11 0.53872 (15) −0.02303 (12) 0.16456 (10) 0.0124 (3) 
C12 0.41784 (15) −0.07508 (11) 0.23187 (10) 0.0121 (3) 
C13 0.41347 (15) 0.07022 (11) 0.32949 (10) 0.0113 (3) 
C14 0.53782 (15) 0.11751 (11) 0.26438 (10) 0.0119 (3) 
C15 0.19528 (15) −0.03352 (11) 0.34531 (10) 0.0119 (3) 
C16 0.11564 (15) 0.03388 (12) 0.29156 (10) 0.0124 (3) 
C17 −0.01974 (15) 0.00798 (12) 0.34468 (10) 0.0135 (3) 
C18 −0.15775 (15) 0.04669 (13) 0.33728 (12) 0.0197 (3) 
H9 −0.2266 −0.0146 0.3613 0.029* 
H11 −0.1511 0.0779 0.2704 0.029* 
H10 −0.1867 0.1024 0.3753 0.029* 
C19 0.17127 (15) 0.11453 (12) 0.20198 (10) 0.0132 (3) 
C20 0.11554 (16) 0.25119 (13) 0.08400 (11) 0.0188 (3) 
H12 0.1443 0.2184 0.027 0.023* 
H13 0.1957 0.2949 0.0857 0.023* 
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C21 −0.00676 (17) 0.32187 (13) 0.08050 (12) 0.0206 (3) 
H14 −0.0875 0.2767 0.0838 0.031* 
H16 0.0173 0.3767 0.0208 0.031* 
H15 −0.0296 0.3582 0.1347 0.031* 
C22 0.85760 (16) 0.41858 (12) 0.40063 (10) 0.0152 (3) 
H17 0.7694 0.4256 0.444 0.018* 
C23 0.92109 (16) 0.32023 (12) 0.40860 (11) 0.0174 (3) 
H18 0.8765 0.2597 0.457 0.021* 
C24 1.05042 (17) 0.31006 (12) 0.34561 (11) 0.0177 (3) 
H19 1.0961 0.2433 0.3525 0.021* 
C25 1.11295 (16) 0.39706 (12) 0.27278 (11) 0.0152 (3) 
H20 1.2003 0.3891 0.2288 0.018* 
C26 1.10150 (15) 0.77518 (12) 0.09529 (11) 0.0150 (3) 
H21 1.1859 0.7652 0.0493 0.018* 
C27 1.03694 (16) 0.87226 (13) 0.08403 (11) 0.0185 (3) 
H22 1.0771 0.9295 0.0309 0.022* 
C28 0.91269 (16) 0.88644 (12) 0.15061 (11) 0.0189 (3) 
H23 0.868 0.9536 0.143 0.023* 
C29 0.85343 (16) 0.80285 (12) 0.22823 (11) 0.0164 (3) 
H24 0.7676 0.8127 0.2729 0.02* 
C30 0.85690 (15) 0.61725 (11) 0.32927 (10) 0.0113 (3) 
C31 1.11608 (15) 0.58694 (12) 0.18297 (10) 0.0131 (3) 
C32 1.04862 (15) 0.49630 (12) 0.26351 (10) 0.0123 (3) 
C33 0.92176 (15) 0.50795 (11) 0.32941 (10) 0.0116 (3) 
C34 0.91894 (15) 0.70497 (12) 0.24094 (10) 0.0120 (3) 
C35 1.04392 (15) 0.69082 (11) 0.17394 (10) 0.0119 (3) 
C36 0.69982 (15) 0.60498 (11) 0.35216 (10) 0.0109 (3) 
C37 0.62199 (15) 0.56608 (11) 0.29806 (10) 0.0129 (3) 
C38 0.48620 (15) 0.56731 (11) 0.35019 (10) 0.0131 (3) 
C39 0.34938 (15) 0.53651 (13) 0.34072 (11) 0.0184 (3) 
H25 0.321 0.462 0.3767 0.028* 
H27 0.3573 0.5406 0.2733 0.028* 
H26 0.2794 0.5866 0.3659 0.028* 
C40 0.68012 (15) 0.53118 (12) 0.20702 (10) 0.0127 (3) 
C41 0.63080 (16) 0.44355 (13) 0.09360 (10) 0.0161 (3) 
H28 0.708 0.3939 0.0965 0.019* 
H29 0.6647 0.5049 0.0383 0.019* 
C42 0.50717 (16) 0.38379 (13) 0.08488 (11) 0.0185 (3) 
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H30 0.4796 0.32 0.1374 0.028* 
H31 0.5326 0.3602 0.0239 0.028* 
H32 0.4291 0.4323 0.0876 0.028* 
N1 0.11438 (12) −0.09462 (10) 0.42317 (9) 0.0147 (3) 
N2 0.61807 (12) 0.62767 (10) 0.43052 (9) 0.0141 (3) 
O1 0.71551 (11) 0.11532 (9) 0.12176 (8) 0.0213 (3) 
O2 −0.02303 (10) −0.06859 (8) 0.42289 (7) 0.0161 (2) 
O3 0.29466 (11) 0.13287 (9) 0.16269 (7) 0.0192 (2) 
O4 0.07022 (11) 0.16608 (9) 0.17063 (7) 0.0180 (2) 
O5 1.22729 (11) 0.57605 (9) 0.12509 (8) 0.0203 (2) 
O6 0.48084 (10) 0.60448 (8) 0.42934 (7) 0.0149 (2) 
O7 0.80195 (11) 0.54218 (9) 0.16192 (7) 0.0191 (2) 
O8 0.58166 (10) 0.48367 (9) 0.18180 (7) 0.0159 (2) 
 
Atomic displacement parameters (Å
2
) 
 
 
U
11
 U
22
 U
33
 U
12
 U
13
 U
23
 
Cl1 0.01769 (19) 0.01571 (18) 0.01612 (19) 0.00367 (14) −0.00459 (15) 0.00155 (14) 
Cl2 0.01699 (19) 0.01912 (19) 0.01480 (18) −0.00256 (14) −0.00484 (14) −0.00744 (14) 
C1 0.0149 (8) 0.0155 (7) 0.0189 (8) −0.0018 (6) −0.0008 (6) −0.0052 (6) 
C2 0.0187 (8) 0.0180 (8) 0.0246 (8) 0.0008 (6) −0.0065 (7) −0.0109 (7) 
C3 0.0176 (8) 0.0238 (8) 0.0177 (8) 0.0046 (6) −0.0035 (6) −0.0117 (7) 
C4 0.0139 (7) 0.0195 (8) 0.0158 (8) 0.0015 (6) −0.0017 (6) −0.0042 (6) 
C5 0.0151 (7) 0.0121 (7) 0.0196 (8) −0.0004 (6) −0.0066 (6) −0.0010 (6) 
C6 0.0223 (8) 0.0120 (7) 0.0230 (8) 0.0006 (6) −0.0116 (7) −0.0065 (6) 
C7 0.0215 (8) 0.0196 (8) 0.0177 (8) 0.0053 (6) −0.0073 (7) −0.0089 (6) 
C8 0.0151 (8) 0.0183 (8) 0.0143 (7) 0.0018 (6) −0.0031 (6) −0.0042 (6) 
C9 0.0116 (7) 0.0113 (7) 0.0114 (7) 0.0018 (5) −0.0026 (6) 0.0000 (5) 
C10 0.0123 (7) 0.0125 (7) 0.0145 (7) 0.0019 (6) −0.0033 (6) −0.0006 (6) 
C11 0.0111 (7) 0.0125 (7) 0.0133 (7) 0.0025 (5) −0.0032 (6) −0.0026 (6) 
C12 0.0122 (7) 0.0111 (7) 0.0125 (7) 0.0034 (5) −0.0028 (6) −0.0029 (6) 
C13 0.0117 (7) 0.0106 (7) 0.0126 (7) 0.0022 (5) −0.0051 (6) −0.0024 (5) 
C14 0.0115 (7) 0.0098 (7) 0.0143 (7) 0.0029 (5) −0.0048 (6) −0.0011 (6) 
C15 0.0137 (7) 0.0094 (7) 0.0118 (7) 0.0010 (5) −0.0014 (6) −0.0039 (5) 
C16 0.0118 (7) 0.0123 (7) 0.0134 (7) 0.0007 (6) −0.0030 (6) −0.0041 (6) 
C17 0.0156 (7) 0.0102 (7) 0.0145 (7) −0.0009 (6) −0.0035 (6) −0.0032 (6) 
C18 0.0116 (7) 0.0235 (8) 0.0230 (8) 0.0019 (6) −0.0029 (6) −0.0058 (7) 
C19 0.0132 (7) 0.0142 (7) 0.0133 (7) 0.0025 (6) −0.0044 (6) −0.0051 (6) 
C20 0.0188 (8) 0.0200 (8) 0.0142 (7) 0.0008 (6) −0.0039 (6) 0.0029 (6) 
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C21 0.0203 (8) 0.0210 (8) 0.0210 (8) 0.0042 (7) −0.0087 (7) −0.0019 (7) 
C22 0.0156 (7) 0.0153 (7) 0.0133 (7) −0.0022 (6) −0.0028 (6) −0.0016 (6) 
C23 0.0227 (8) 0.0126 (7) 0.0162 (7) −0.0032 (6) −0.0075 (6) 0.0014 (6) 
C24 0.0229 (8) 0.0111 (7) 0.0229 (8) 0.0039 (6) −0.0121 (7) −0.0046 (6) 
C25 0.0133 (7) 0.0156 (7) 0.0183 (8) 0.0006 (6) −0.0051 (6) −0.0066 (6) 
C26 0.0118 (7) 0.0176 (7) 0.0148 (7) −0.0026 (6) −0.0029 (6) −0.0023 (6) 
C27 0.0184 (8) 0.0165 (8) 0.0169 (8) −0.0033 (6) −0.0038 (6) 0.0030 (6) 
C28 0.0193 (8) 0.0131 (7) 0.0234 (8) 0.0017 (6) −0.0066 (7) −0.0011 (6) 
C29 0.0140 (7) 0.0144 (7) 0.0188 (8) 0.0008 (6) −0.0014 (6) −0.0035 (6) 
C30 0.0119 (7) 0.0125 (7) 0.0104 (7) −0.0005 (5) −0.0028 (6) −0.0047 (6) 
C31 0.0119 (7) 0.0142 (7) 0.0148 (7) −0.0013 (6) −0.0047 (6) −0.0050 (6) 
C32 0.0120 (7) 0.0119 (7) 0.0147 (7) −0.0016 (5) −0.0057 (6) −0.0040 (6) 
C33 0.0126 (7) 0.0112 (7) 0.0125 (7) −0.0013 (5) −0.0058 (6) −0.0029 (6) 
C34 0.0117 (7) 0.0113 (7) 0.0134 (7) −0.0027 (5) −0.0042 (6) −0.0026 (6) 
C35 0.0117 (7) 0.0113 (7) 0.0129 (7) −0.0023 (5) −0.0039 (6) −0.0025 (6) 
C36 0.0123 (7) 0.0076 (6) 0.0117 (7) −0.0002 (5) −0.0021 (6) −0.0012 (5) 
C37 0.0140 (7) 0.0108 (7) 0.0130 (7) −0.0009 (6) −0.0032 (6) −0.0016 (6) 
C38 0.0155 (7) 0.0103 (7) 0.0130 (7) 0.0000 (6) −0.0040 (6) −0.0012 (6) 
C39 0.0121 (7) 0.0230 (8) 0.0196 (8) −0.0010 (6) −0.0039 (6) −0.0043 (7) 
C40 0.0135 (7) 0.0132 (7) 0.0111 (7) 0.0000 (6) −0.0042 (6) −0.0012 (6) 
C41 0.0155 (8) 0.0219 (8) 0.0126 (7) 0.0019 (6) −0.0041 (6) −0.0073 (6) 
C42 0.0187 (8) 0.0209 (8) 0.0186 (8) 0.0002 (6) −0.0074 (6) −0.0074 (6) 
N1 0.0097 (6) 0.0147 (6) 0.0171 (6) 0.0007 (5) −0.0008 (5) −0.0021 (5) 
N2 0.0099 (6) 0.0147 (6) 0.0164 (6) −0.0025 (5) −0.0012 (5) −0.0040 (5) 
O1 0.0176 (6) 0.0192 (6) 0.0212 (6) −0.0062 (5) 0.0043 (5) −0.0048 (5) 
O2 0.0099 (5) 0.0159 (5) 0.0190 (6) −0.0005 (4) −0.0004 (4) −0.0012 (4) 
O3 0.0133 (5) 0.0226 (6) 0.0171 (6) 0.0014 (4) −0.0021 (4) 0.0030 (5) 
O4 0.0131 (5) 0.0197 (6) 0.0170 (6) 0.0005 (4) −0.0036 (4) 0.0045 (4) 
O5 0.0156 (6) 0.0189 (6) 0.0210 (6) 0.0003 (4) 0.0031 (5) −0.0039 (5) 
O6 0.0107 (5) 0.0171 (5) 0.0167 (5) 0.0003 (4) −0.0017 (4) −0.0061 (4) 
O7 0.0139 (5) 0.0273 (6) 0.0168 (6) −0.0021 (5) −0.0019 (4) −0.0097 (5) 
O8 0.0132 (5) 0.0222 (6) 0.0144 (5) −0.0010 (4) −0.0038 (4) −0.0084 (4) 
 
Geometric parameters (Å, º)  
 
Cl1—C9 1.842 (3) C22—C23 1.379 (3) 
Cl2—C30 1.840 (3) C22—C33 1.396 (3) 
C1—C2 1.383 (3) C22—H17 0.95 
C1—C12 1.391 (3) C23—C24 1.388 (3) 
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C1—H1 0.95 C23—H18 0.95 
C2—C3 1.390 (3) C24—C25 1.385 (3) 
C2—H2 0.95 C24—H19 0.95 
C3—C4 1.378 (3) C25—C32 1.394 (3) 
C3—H3 0.95 C25—H20 0.95 
C4—C11 1.399 (3) C26—C27 1.373 (3) 
C4—H4 0.95 C26—C35 1.400 (3) 
C5—C6 1.377 (3) C26—H21 0.95 
C5—C14 1.396 (3) C27—C28 1.389 (3) 
C5—H5 0.95 C27—H22 0.95 
C6—C7 1.391 (3) C28—C29 1.389 (3) 
C6—H6 0.95 C28—H23 0.95 
C7—C8 1.379 (3) C29—C34 1.388 (3) 
C7—H7 0.95 C29—H24 0.95 
C8—C13 1.392 (3) C30—C33 1.509 (3) 
C8—H8 0.95 C30—C36 1.514 (3) 
C9—C13 1.511 (3) C30—C34 1.517 (3) 
C9—C15 1.513 (3) C31—O5 1.225 (2) 
C9—C12 1.514 (3) C31—C35 1.482 (3) 
C10—O1 1.230 (2) C31—C32 1.483 (3) 
C10—C11 1.477 (3) C32—C33 1.394 (3) 
C10—C14 1.479 (3) C34—C35 1.397 (3) 
C11—C12 1.402 (3) C36—N2 1.307 (3) 
C13—C14 1.395 (3) C36—C37 1.428 (3) 
C15—N1 1.310 (3) C37—C38 1.362 (3) 
C15—C16 1.436 (3) C37—C40 1.474 (3) 
C16—C17 1.366 (3) C38—O6 1.347 (3) 
C16—C19 1.472 (3) C38—C39 1.483 (3) 
C17—O2 1.346 (3) C39—H25 0.98 
C17—C18 1.484 (3) C39—H27 0.98 
C18—H9 0.98 C39—H26 0.98 
C18—H11 0.98 C40—O7 1.208 (3) 
C18—H10 0.98 C40—O8 1.341 (2) 
C19—O3 1.210 (3) C41—O8 1.460 (3) 
C19—O4 1.337 (2) C41—C42 1.510 (3) 
C20—O4 1.462 (3) C41—H28 0.99 
C20—C21 1.507 (3) C41—H29 0.99 
C20—H12 0.99 C42—H30 0.98 
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C20—H13 0.99 C42—H31 0.98 
C21—H14 0.98 C42—H32 0.98 
C21—H16 0.98 N1—O2 1.410 (3) 
C21—H15 0.98 N2—O6 1.415 (3) 
C2—C1—C12 120.24 (16) C22—C23—C24 119.75 (16) 
C2—C1—H1 119.9 C22—C23—H18 120.1 
C12—C1—H1 119.9 C24—C23—H18 120.1 
C1—C2—C3 120.34 (17) C25—C24—C23 120.12 (16) 
C1—C2—H2 119.8 C25—C24—H19 119.9 
C3—C2—H2 119.8 C23—C24—H19 119.9 
C4—C3—C2 119.90 (17) C24—C25—C32 120.44 (17) 
C4—C3—H3 120.1 C24—C25—H20 119.8 
C2—C3—H3 120.1 C32—C25—H20 119.8 
C3—C4—C11 120.51 (16) C27—C26—C35 120.53 (17) 
C3—C4—H4 119.7 C27—C26—H21 119.7 
C11—C4—H4 119.7 C35—C26—H21 119.7 
C6—C5—C14 120.48 (17) C26—C27—C28 119.75 (16) 
C6—C5—H5 119.8 C26—C27—H22 120.1 
C14—C5—H5 119.8 C28—C27—H22 120.1 
C5—C6—C7 119.76 (16) C27—C28—C29 120.30 (17) 
C5—C6—H6 120.1 C27—C28—H23 119.9 
C7—C6—H6 120.1 C29—C28—H23 119.9 
C8—C7—C6 120.24 (16) C34—C29—C28 120.37 (17) 
C8—C7—H7 119.9 C34—C29—H24 119.8 
C6—C7—H7 119.9 C28—C29—H24 119.8 
C7—C8—C13 120.39 (17) C33—C30—C36 110.70 (14) 
C7—C8—H8 119.8 C33—C30—C34 115.52 (15) 
C13—C8—H8 119.8 C36—C30—C34 111.86 (12) 
C13—C9—C15 110.92 (13) C33—C30—Cl2 104.31 (12) 
C13—C9—C12 115.38 (14) C36—C30—Cl2 108.80 (11) 
C15—C9—C12 111.79 (13) C34—C30—Cl2 105.01 (16) 
C13—C9—Cl1 104.50 (15) O5—C31—C35 120.93 (15) 
C15—C9—Cl1 108.42 (11) O5—C31—C32 121.13 (16) 
C12—C9—Cl1 105.19 (16) C35—C31—C32 117.94 (16) 
O1—C10—C11 120.96 (16) C25—C32—C33 119.39 (15) 
O1—C10—C14 120.87 (16) C25—C32—C31 119.16 (17) 
C11—C10—C14 118.17 (15) C33—C32—C31 121.44 (15) 
C4—C11—C12 119.32 (16) C32—C33—C22 119.57 (16) 
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C4—C11—C10 119.27 (15) C32—C33—C30 121.18 (14) 
C12—C11—C10 121.40 (16) C22—C33—C30 119.13 (17) 
C1—C12—C11 119.66 (16) C29—C34—C35 119.27 (15) 
C1—C12—C9 119.01 (15) C29—C34—C30 119.49 (16) 
C11—C12—C9 121.29 (15) C35—C34—C30 121.19 (15) 
C8—C13—C14 119.44 (16) C34—C35—C26 119.78 (16) 
C8—C13—C9 118.83 (15) C34—C35—C31 121.35 (15) 
C14—C13—C9 121.65 (15) C26—C35—C31 118.86 (16) 
C13—C14—C5 119.61 (16) N2—C36—C37 111.56 (18) 
C13—C14—C10 121.15 (15) N2—C36—C30 120.83 (14) 
C5—C14—C10 119.23 (15) C37—C36—C30 127.58 (15) 
N1—C15—C16 111.56 (18) C38—C37—C36 104.65 (18) 
N1—C15—C9 120.59 (14) C38—C37—C40 129.08 (14) 
C16—C15—C9 127.80 (14) C36—C37—C40 126.26 (17) 
C17—C16—C15 103.98 (17) O6—C38—C37 109.06 (15) 
C17—C16—C19 129.32 (14) O6—C38—C39 115.39 (13) 
C15—C16—C19 126.66 (16) C37—C38—C39 135.54 (17) 
O2—C17—C16 109.47 (15) C38—C39—H25 109.5 
O2—C17—C18 115.27 (13) C38—C39—H27 109.5 
C16—C17—C18 135.22 (17) H25—C39—H27 109.5 
C17—C18—H9 109.5 C38—C39—H26 109.5 
C17—C18—H11 109.5 H25—C39—H26 109.5 
H9—C18—H11 109.5 H27—C39—H26 109.5 
C17—C18—H10 109.5 O7—C40—O8 124.38 (17) 
H9—C18—H10 109.5 O7—C40—C37 123.99 (14) 
H11—C18—H10 109.5 O8—C40—C37 111.61 (16) 
O3—C19—O4 124.32 (17) O8—C41—C42 106.17 (14) 
O3—C19—C16 123.36 (14) O8—C41—H28 110.5 
O4—C19—C16 112.31 (16) C42—C41—H28 110.5 
O4—C20—C21 107.02 (15) O8—C41—H29 110.5 
O4—C20—H12 110.3 C42—C41—H29 110.5 
C21—C20—H12 110.3 H28—C41—H29 108.7 
O4—C20—H13 110.3 C41—C42—H30 109.5 
C21—C20—H13 110.3 C41—C42—H31 109.5 
H12—C20—H13 108.6 H30—C42—H31 109.5 
C20—C21—H14 109.5 C41—C42—H32 109.5 
C20—C21—H16 109.5 H30—C42—H32 109.5 
H14—C21—H16 109.5 H31—C42—H32 109.5 
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C20—C21—H15 109.5 C15—N1—O2 105.50 (15) 
H14—C21—H15 109.5 C36—N2—O6 105.34 (15) 
H16—C21—H15 109.5 C17—O2—N1 109.49 (11) 
C23—C22—C33 120.64 (18) C19—O4—C20 116.30 (15) 
C23—C22—H17 119.7 C38—O6—N2 109.39 (11) 
C33—C22—H17 119.7 C40—O8—C41 115.37 (14) 
C12—C1—C2—C3 −1.5 (2) O5—C31—C32—C25 −0.4 (2) 
C1—C2—C3—C4 1.4 (2) C35—C31—C32—C25 178.88 (13) 
C2—C3—C4—C11 −0.1 (2) O5—C31—C32—C33 −179.71 (14) 
C14—C5—C6—C7 −0.8 (2) C35—C31—C32—C33 −0.4 (2) 
C5—C6—C7—C8 1.7 (2) C25—C32—C33—C22 −3.3 (2) 
C6—C7—C8—C13 −0.1 (2) C31—C32—C33—C22 176.02 (13) 
C3—C4—C11—C12 −1.3 (2) C25—C32—C33—C30 172.62 (13) 
C3—C4—C11—C10 178.72 (14) C31—C32—C33—C30 −8.1 (2) 
O1—C10—C11—C4 −3.3 (2) C23—C22—C33—C32 2.5 (2) 
C14—C10—C11—C4 176.57 (13) C23—C22—C33—C30 −173.48 (13) 
O1—C10—C11—C12 176.69 (14) C36—C30—C33—C32 142.29 (15) 
C14—C10—C11—C12 −3.4 (2) C34—C30—C33—C32 13.87 (19) 
C2—C1—C12—C11 0.1 (2) Cl2—C30—C33—C32 −100.84 (19) 
C2—C1—C12—C9 −177.61 (14) C36—C30—C33—C22 −41.77 (19) 
C4—C11—C12—C1 1.2 (2) C34—C30—C33—C22 −170.19 (13) 
C10—C11—C12—C1 −178.76 (13) Cl2—C30—C33—C22 75.1 (2) 
C4—C11—C12—C9 178.92 (13) C28—C29—C34—C35 −1.1 (2) 
C10—C11—C12—C9 −1.1 (2) C28—C29—C34—C30 176.39 (14) 
C13—C9—C12—C1 −173.93 (13) C33—C30—C34—C29 170.70 (13) 
C15—C9—C12—C1 −45.95 (19) C36—C30—C34—C29 42.85 (19) 
Cl1—C9—C12—C1 71.50 (19) Cl2—C30—C34—C29 −74.99 (18) 
C13—C9—C12—C11 8.36 (19) C33—C30—C34—C35 −11.90 (19) 
C15—C9—C12—C11 136.33 (15) C36—C30—C34—C35 −139.74 (15) 
Cl1—C9—C12—C11 −106.21 (18) Cl2—C30—C34—C35 102.41 (17) 
C7—C8—C13—C14 −2.3 (2) C29—C34—C35—C26 0.2 (2) 
C7—C8—C13—C9 174.37 (13) C30—C34—C35—C26 −177.26 (13) 
C15—C9—C13—C8 43.18 (18) C29—C34—C35—C31 −178.46 (13) 
C12—C9—C13—C8 171.59 (13) C30—C34—C35—C31 4.1 (2) 
Cl1—C9—C13—C8 −73.44 (19) C27—C26—C35—C34 0.8 (2) 
C15—C9—C13—C14 −140.27 (15) C27—C26—C35—C31 179.40 (14) 
C12—C9—C13—C14 −11.87 (19) O5—C31—C35—C34 −178.32 (14) 
Cl1—C9—C13—C14 103.10 (19) C32—C31—C35—C34 2.4 (2) 
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C8—C13—C14—C5 3.1 (2) O5—C31—C35—C26 3.1 (2) 
C9—C13—C14—C5 −173.44 (13) C32—C31—C35—C26 −176.20 (13) 
C8—C13—C14—C10 −175.52 (13) C33—C30—C36—N2 114.47 (16) 
C9—C13—C14—C10 8.0 (2) C34—C30—C36—N2 −115.2 (2) 
C6—C5—C14—C13 −1.6 (2) Cl2—C30—C36—N2 0.40 (17) 
C6—C5—C14—C10 177.06 (13) C33—C30—C36—C37 −63.2 (2) 
O1—C10—C14—C13 179.83 (13) C34—C30—C36—C37 67.1 (2) 
C11—C10—C14—C13 0.0 (2) Cl2—C30—C36—C37 −177.30 (12) 
O1—C10—C14—C5 1.2 (2) N2—C36—C37—C38 0.10 (16) 
C11—C10—C14—C5 −178.63 (13) C30—C36—C37—C38 177.98 (13) 
C13—C9—C15—N1 −111.82 (19) N2—C36—C37—C40 −178.89 (13) 
C12—C9—C15—N1 117.9 (2) C30—C36—C37—C40 −1.0 (2) 
Cl1—C9—C15—N1 2.37 (17) C36—C37—C38—O6 0.37 (16) 
C13—C9—C15—C16 65.4 (2) C40—C37—C38—O6 179.32 (13) 
C12—C9—C15—C16 −64.9 (2) C36—C37—C38—C39 −178.35 (16) 
Cl1—C9—C15—C16 179.60 (12) C40—C37—C38—C39 0.6 (3) 
N1—C15—C16—C17 0.40 (16) C38—C37—C40—O7 173.17 (15) 
C9—C15—C16—C17 −177.04 (14) C36—C37—C40—O7 −8.1 (2) 
N1—C15—C16—C19 178.26 (14) C38—C37—C40—O8 −8.2 (2) 
C9—C15—C16—C19 0.8 (2) C36—C37—C40—O8 170.51 (13) 
C15—C16—C17—O2 −0.56 (16) C16—C15—N1—O2 −0.08 (15) 
C19—C16—C17—O2 −178.34 (14) C9—C15—N1—O2 177.56 (12) 
C15—C16—C17—C18 176.92 (17) C37—C36—N2—O6 −0.50 (15) 
C19—C16—C17—C18 −0.9 (3) C30—C36—N2—O6 −178.54 (11) 
C17—C16—C19—O3 177.55 (15) C16—C17—O2—N1 0.55 (16) 
C15—C16—C19—O3 0.2 (2) C18—C17—O2—N1 −177.50 (12) 
C17—C16—C19—O4 −1.2 (2) C15—N1—O2—C17 −0.28 (15) 
C15—C16—C19—O4 −178.51 (13) O3—C19—O4—C20 −1.2 (2) 
C33—C22—C23—C24 0.4 (2) C16—C19—O4—C20 177.50 (12) 
C22—C23—C24—C25 −2.5 (2) C21—C20—O4—C19 −161.22 (13) 
C23—C24—C25—C32 1.7 (2) C37—C38—O6—N2 −0.69 (15) 
C35—C26—C27—C28 −0.7 (2) C39—C38—O6—N2 178.32 (12) 
C26—C27—C28—C29 −0.2 (2) C36—N2—O6—C38 0.73 (14) 
C27—C28—C29—C34 1.1 (2) O7—C40—O8—C41 0.3 (2) 
C24—C25—C32—C33 1.2 (2) C37—C40—O8—C41 −178.28 (12) 
C24—C25—C32—C31 −178.12 (13) C42—C41—O8—C40 174.26 (12) 
 
